CAPR vs. CLSD, PRPH, LPTX, EYEN, NRBO, GHRS, WVE, PLRX, LBPH, and PAHC
Should you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include Clearside Biomedical (CLSD), ProPhase Labs (PRPH), Leap Therapeutics (LPTX), Eyenovia (EYEN), NeuroBo Pharmaceuticals (NRBO), GH Research (GHRS), Wave Life Sciences (WVE), Pliant Therapeutics (PLRX), Longboard Pharmaceuticals (LBPH), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical preparations" industry.
Clearside Biomedical (NASDAQ:CLSD) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.
Clearside Biomedical presently has a consensus target price of $4.50, indicating a potential upside of 268.85%. Capricor Therapeutics has a consensus target price of $21.75, indicating a potential upside of 315.08%. Given Clearside Biomedical's higher possible upside, analysts clearly believe Capricor Therapeutics is more favorable than Clearside Biomedical.
18.8% of Clearside Biomedical shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 9.2% of Clearside Biomedical shares are held by company insiders. Comparatively, 12.0% of Capricor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Capricor Therapeutics has a net margin of -89.72% compared to Capricor Therapeutics' net margin of -413.73%. Capricor Therapeutics' return on equity of 0.00% beat Clearside Biomedical's return on equity.
In the previous week, Capricor Therapeutics had 1 more articles in the media than Clearside Biomedical. MarketBeat recorded 1 mentions for Capricor Therapeutics and 0 mentions for Clearside Biomedical. Clearside Biomedical's average media sentiment score of 0.59 beat Capricor Therapeutics' score of 0.00 indicating that Capricor Therapeutics is being referred to more favorably in the news media.
Capricor Therapeutics has higher revenue and earnings than Clearside Biomedical. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Clearside Biomedical, indicating that it is currently the more affordable of the two stocks.
Clearside Biomedical received 11 more outperform votes than Capricor Therapeutics when rated by MarketBeat users. Likewise, 67.17% of users gave Clearside Biomedical an outperform vote while only 62.73% of users gave Capricor Therapeutics an outperform vote.
Clearside Biomedical has a beta of 2.36, suggesting that its stock price is 136% more volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 3.96, suggesting that its stock price is 296% more volatile than the S&P 500.
Summary
Capricor Therapeutics beats Clearside Biomedical on 10 of the 16 factors compared between the two stocks.
Get Capricor Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Capricor Therapeutics Competitors List
Related Companies and Tools
